Welcome to our dedicated page for Celcuity SEC filings (Ticker: CELC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Celcuity Inc means dissecting dense disclosures on trial endpoints, R&D burn, and licensing terms—details that can span hundreds of pages. If you have ever wondered where to locate the latest Celcuity quarterly earnings report 10-Q filing or how to decode a 300-page 10-K, you are not alone.
Stock Titan’s AI engine digests every sentence the moment it hits EDGAR, then delivers concise explanations in plain English. The result: Celcuity SEC filings explained simply. Whether you need understanding Celcuity SEC documents with AI or instant alerts on Celcuity Form 4 insider transactions real-time, our platform turns regulatory text into actionable context.
- 10-K: Get the Celcuity annual report 10-K simplified—clinical pipeline progress, cash runway, and risk factors, all summarized.
- 10-Q: Compare quarter-over-quarter R&D spend with automated charts and Celcuity earnings report filing analysis.
- 8-K: Stay ahead with Celcuity 8-K material events explained—from Phase 3 data releases to financing rounds.
- Form 4: Monitor Celcuity insider trading Form 4 transactions and track each Celcuity executive stock transactions Form 4 in real time.
- DEF 14A: Review the Celcuity proxy statement executive compensation section with AI-highlighted pay metrics.
Every filing is updated the moment Celcuity submits it, complete with AI-powered summaries, key-metric extractions, and side-by-side document comparisons. Skip the biotech jargon, save hours of manual reading, and focus on the insights that move Celcuity’s valuation.
Celcuity Inc. (CELC) filed an 8-K detailing several capital-raising and financing actions dated 28 Jul 2025.
Loan amendment: The company executed a Second Amendment to its Amended & Restated Loan and Security Agreement with Innovatus and Oxford Finance. Key changes: (i) allows issuance of $150 m aggregate principal Convertible Senior Notes due 2031 and related capped-call transactions; (ii) permits equity conversion of the notes solely into common shares (cash only for fractional shares); (iii) requires a one-time $25 k amendment fee paid to Oxford; and (iv) extends to 9 May 2026 Innovatus’ option to convert up to 20 % of Term A principal into CELC stock at $10.00 per share.
Capital markets activity: Celcuity launched a concurrent offering for $150 m of the Notes plus $75 m of common stock. Proceeds would strengthen liquidity and fund operations.
Additional debt capacity: Management believes the Phase 3 VIKTORIA-1 data achieve the “Term D Milestone,” enabling a $30 m Term D Loan draw by 31 Aug 2025.
Preliminary cash position: Cash, equivalents and short-term investments are expected at ~<$168.4 m> on 30 Jun 2025 versus $283.1 m a year earlier (-41 %). Figures are unaudited and subject to change.
Forward-looking statements caution that the offerings may not close, the Term D draw might not occur, and final June-quarter financials could differ.
FAQ
What is the current stock price of Celcuity (CELC)?
What is the market cap of Celcuity (CELC)?
